摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S)-3,3,3-trifluoro-2-methylpropanoic acid | 160290-20-0

中文名称
——
中文别名
——
英文名称
(2S)-3,3,3-trifluoro-2-methylpropanoic acid
英文别名
(S)-α-trifluoromethylpropanoic acid;(S)-3,3,3-trifluoro-2-methylpropanoic acid
(2S)-3,3,3-trifluoro-2-methylpropanoic acid化学式
CAS
160290-20-0
化学式
C4H5F3O2
mdl
——
分子量
142.078
InChiKey
DQOGDQIDOONUSK-REOHCLBHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    139.5±35.0 °C(Predicted)
  • 密度:
    1.340±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    重氮甲烷(2S)-3,3,3-trifluoro-2-methylpropanoic acid乙醚 为溶剂, 生成 (S)-3,3,3-Trifluoro-2-methyl-propionic acid methyl ester
    参考文献:
    名称:
    Preparation of Optically Active 2-(Trifluoromethyl)alkan-1-ols by Catalytic Asymmetric Hydrogenation.
    摘要:
    在Ru-2, 2'-双(二苯基膦)-1, 1'-联萘(Ru-BINAP)和Rh-BINAP的催化下,对(E)-2-(三氟甲基)-2-烯-1-醇进行了加氢反应,获得了良好的对映体过量(ee为71-83%)。在Ru-BINAP的催化下,2-(三氟甲基)丙烯酸被转化为相应的饱和酸,其酯化和还原反应产生了光学活性2-(三氟甲基)-1-丙醇,ee为80%。
    DOI:
    10.1248/cpb.44.477
  • 作为产物:
    描述:
    (2S,3S)-1,3-dihydroxybutan-2-aminium (S)-3,3,3-trifluoro-2-methylpropanoate 在 盐酸 作用下, 以 为溶剂, 以100%的产率得到(2S)-3,3,3-trifluoro-2-methylpropanoic acid
    参考文献:
    名称:
    Synthesis of ( R )- and ( S )-α-trifluoromethyl propanoic acids via asymmetric hydrogenation followed by salt resolution
    摘要:
    A highly enantioselective synthesis of (R)- and (S)-alpha-trifluoromethyl (CF3) propanoic acids has been achieved via asymmetric hydrogenation of 2-trifluoromethylacrylic acid using RuBINAP-Cl-2 catalyst followed by salt resolution with threoninol. Both enantiomers can be obtained as threoninol salts in good yield and with high enantiomeric excess. Amide coupling conditions that minimize racemization of the chiral acid have also been developed. (C) 2016 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetasy.2016.07.004
点击查看最新优质反应信息

文献信息

  • PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT
    申请人:Janssen Pharmaceutica NV
    公开号:US20190382350A1
    公开(公告)日:2019-12-19
    The present invention comprises compounds of Formula I. wherein: R 1 , R 3 , R 4 , R 5 , R 6 , and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    本发明涵盖了Formula I的化合物。 其中: R1、R3、R4、R5、R6和Q在规范中有定义。 该发明还涵盖了一种治疗或改善ROR-γ-t介导的综合症、疾病或疾病的方法,包括综合症、疾病或疾病选自类风湿性关节炎、银屑病性关节炎和牛皮癣的群组。该发明还涵盖了通过给哺乳动物施用至少一种Formula I化合物的治疗有效量来调节RORγt活性的方法。
  • PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT
    申请人:Janssen Pharmaceutica NV
    公开号:US20190382349A1
    公开(公告)日:2019-12-19
    The present invention comprises compounds of Formula I. wherein: R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    本发明涵盖了Formula I的化合物。 其中: R1、R3、R4、R5、R6、R7、R8和Q在规范中有定义。 该发明还涵盖了一种治疗或改善ROR-γ-t介导的综合征、疾病或疾病的方法,包括综合征、疾病或疾病选自类风湿性关节炎、银屑病性关节炎和牛皮癣的群组。该发明还涵盖了通过给哺乳动物施用至少一种Formula I化合物的治疗有效量来调节RORγt活性的方法。
  • Lipase mediated preparation of the enantiomers of 3,3,3-trifluoro-2-methylpropanoic acid
    作者:Petr Beier、Alexandra M. Z. Slawin、David O’Hagan
    DOI:10.1016/j.tetasy.2004.07.014
    日期:2004.8
    The preparation of both enantiomers of 3,3,3-trifluoro-2-methylpropanoic acid by a lipase mediated kinetic resolution of the racemate is described.
    描述了通过脂肪酶介导的外消旋体的动力学拆分制备3,3,3-三氟-2-甲基丙酸的两种对映体。
  • Synthesis of ( R )- and ( S )-α-trifluoromethyl propanoic acids via asymmetric hydrogenation followed by salt resolution
    作者:Ming Z. Chen、Neal W. Sach、Philippe Nuhant、Olugbeminiyi O. Fadeyi、John Trujillo、Vincent Lombardo、Louise Bernier、Ray Unwalla、Andrew C. Flick
    DOI:10.1016/j.tetasy.2016.07.004
    日期:2016.10
    A highly enantioselective synthesis of (R)- and (S)-alpha-trifluoromethyl (CF3) propanoic acids has been achieved via asymmetric hydrogenation of 2-trifluoromethylacrylic acid using RuBINAP-Cl-2 catalyst followed by salt resolution with threoninol. Both enantiomers can be obtained as threoninol salts in good yield and with high enantiomeric excess. Amide coupling conditions that minimize racemization of the chiral acid have also been developed. (C) 2016 Elsevier Ltd. All rights reserved.
  • Preparation of Optically Active 2-(Trifluoromethyl)alkan-1-ols by Catalytic Asymmetric Hydrogenation.
    作者:Katsuhiko ISEKI、Yoshichika KUROKI、Takabumi NAGAI、Yoshiro KOBAYASHI
    DOI:10.1248/cpb.44.477
    日期:——
    The hydrogenation of (E)-2-(trifluoromethyl)alk-2-en-1-ols catalyzed by Ru-2, 2'-bis(diphynylphosphino)-1, 1'-binaphthyl (Ru-BINAP) and Rh-BINAP was carried out with good enantiomeric excess (71-83% ee). Ru-BINAP-catalyzed hydrogenation converted 2-(trifluoromethyl)acrylic acid to the corresponding saturated acid whose esterification and reduction provided optically active 2-(trifluoromethyl)propan-1-ol in 80% ee.
    在Ru-2, 2'-双(二苯基膦)-1, 1'-联萘(Ru-BINAP)和Rh-BINAP的催化下,对(E)-2-(三氟甲基)-2-烯-1-醇进行了加氢反应,获得了良好的对映体过量(ee为71-83%)。在Ru-BINAP的催化下,2-(三氟甲基)丙烯酸被转化为相应的饱和酸,其酯化和还原反应产生了光学活性2-(三氟甲基)-1-丙醇,ee为80%。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物